Given that monocyte and neutrophil subsets in SLE patients are key drivers of inflammation, understanding how microRNA changes in patients regulate IRF protein levels and hence contribute to myeloid cell development may be key in uncovering novel therapeutic targets. The gene discussed is TRIM63; the disease is systemic lupus erythematosus.